Metabolic / Longevity · Research guide

SS-31 peptide: Metabolic / Longevity research guide

SS-31 is listed in our catalogue under “Metabolic / Longevity.” In scientific publications it is discussed in technical language; this page translates the general themes into everyday wording while staying faithful to research-only framing.

Plain-language snapshot

One-paragraph overview from our research datasheet—still scientific, but faster to read than the full mechanism list below.

What shows up in scientific writing (general background)

Many readers want context before diving into pathways. The list below summarises what researchers and reviewers discuss—cells, animals, and (for some drug-class molecules) formal clinical trials. It is not a promise of results for any individual.

Typical study contexts & reported directions

• Mitochondrial stress, NAD+/redox biology, and nutrient-sensing pathways in ageing or metabolic disease models.
• Often measured through enzyme activity, gene expression, or endurance-style readouts in animals—not lifestyle advice.
• Peer-reviewed preclinical work sometimes describes experiments that track whether selectively binds cardiolipin on the inner mitochondrial membrane to stabilize cristae architecture
• Peer-reviewed preclinical work sometimes describes experiments that track whether reduces cardiolipin peroxidation and preserves oxidative phosphorylation coupling efficiency
• Peer-reviewed preclinical work sometimes describes experiments that track whether enhances ATP production by stabilizing ETC supercomplexes (Complex I/III, Complex III/IV)
• Peer-reviewed preclinical work sometimes describes experiments that track whether fDA-approved (Forzinity) for Barth syndrome based on TAZPOWER trial muscle strength data

Why Metabolic / Longevity research discusses this compound

Researchers study these compounds for mitochondrial function, nutrient sensing, and cellular energy stress responses -often in ageing or metabolic disease models.

Themes from preclinical literature (technical)

Below are mechanistic bullet points as they appear in our product reference material -useful for researchers comparing pathways. They are not simplified health claims.

• Selectively binds cardiolipin on the inner mitochondrial membrane to stabilize cristae architecture
• Reduces cardiolipin peroxidation and preserves oxidative phosphorylation coupling efficiency
• Enhances ATP production by stabilizing ETC supercomplexes (Complex I/III, Complex III/IV)
• FDA-approved (Forzinity) for Barth syndrome based on TAZPOWER trial muscle strength data
• Reverses diastolic cardiac dysfunction after 8 weeks of treatment in aged mouse models
• Reduces mitochondrial ROS production without acting as a direct free radical scavenger

Typical handling notes (from our datasheet)

Storage: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. ~5% degradation per year refrigerated. - see our storage guide for best practices on temperature, light, and shelf life.

Typical research dosing discussion (literature-style): 40 mg subcutaneous injection (FDA-approved dose for ≥30 kg) · Once daily (per Forzinity prescribing information) · No hepatic metabolism observed in vitro. Not a substrate of major CYP enzymes. MATE1 inhibitor (IC₅₀ 3.53 μM). Dose reduction by 50% recommended for severe renal impairment (eGFR <30 mL/min). MW 639.8 Da (free base) / 749.2 Da (trihydrochloride salt). Clinical trial doses ranged from 0.01–0.25 mg/kg/h IV (MMPOWER) to 40 mg SC daily (TAZPOWER). Most common adverse event is mild injection site reactions.

For preparation, follow the step-by-step reconstitution guide and use the reconstitution calculator to confirm draw volumes. Review subcutaneous injection basics for technique, and always verify batch purity by reading the COA.

Frequently asked questions

Also known as: SS-31, Elamipretide, MTP-131, Bendavia, Forzinity, D-Arg-Dmt-Lys-Phe-NH₂, Szeto-Schiller Peptide 31, Elamipretide Hydrochloride